Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Pumphrey

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
European Journal of Immunology|September 30, 2011
Natural variations at position 93 of the invariant Vα24-Jα18 α chain of human iNKT-cell TCRs strongly impact on CD1d bindingJoseph P Sanderson, Kathrin Waldburger-Hauri, Diana Garzón, et al.
FEBS Letters|June 1, 1999
Differential association of cytoplasmic signalling molecules SHP-1, SHP-2, SHIP and phospholipase C-gamma1 with PECAM-1/CD31N J Pumphrey, V Taylor, S Freeman, et al.
Clinical and Experimental Immunology|December 16, 2014
T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cellsM P Tan, A B Gerry, J E Brewer, et al.
Hepatology (Baltimore, Md.)|December 19, 2018
Tuning T-Cell Receptor Affinity to Optimize Clinical Risk-Benefit When Targeting Alpha-Fetoprotein-Positive Liver CancerRoslin Y Docta, Tiago Ferronha, Joseph P Sanderson, et al.
Plos One|April 4, 2024
Selection, engineering, and in vivo testing of a human leukocyte antigen-independent T-cell receptor recognizing human mesothelinMartyn J Hiscox, Alexandra Wasmuth, Chris L Williams, et al.
Protein & Cell|January 8, 2011
High affinity soluble ILT2 receptor: a potent inhibitor of CD8(+) T cell activationRuth K Moysey, Yi Li, Samantha J Paston, et al.
Blood|June 18, 2013
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanomaGerald P Linette, Edward A Stadtmauer, Marcela V Maus, et al.
Science Translational Medicine|August 9, 2013
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cellsBrian J Cameron, Andrew B Gerry, Joseph Dukes, et al.
Nature Medicine|May 8, 2012
Monoclonal TCR-redirected tumor cell killingNathaniel Liddy, Giovanna Bossi, Katherine J Adams, et al.
Nature Medicine|July 21, 2015
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myelomaAaron P Rapoport, Edward A Stadtmauer, Gwendolyn K Binder-Scholl, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
European Journal of Immunology|September 30, 2011
Natural variations at position 93 of the invariant Vα24-Jα18 α chain of human iNKT-cell TCRs strongly impact on CD1d bindingJoseph P Sanderson, Kathrin Waldburger-Hauri, Diana Garzón, et al.
FEBS Letters|June 1, 1999
Differential association of cytoplasmic signalling molecules SHP-1, SHP-2, SHIP and phospholipase C-gamma1 with PECAM-1/CD31N J Pumphrey, V Taylor, S Freeman, et al.
Clinical and Experimental Immunology|December 16, 2014
T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cellsM P Tan, A B Gerry, J E Brewer, et al.
Hepatology (Baltimore, Md.)|December 19, 2018
Tuning T-Cell Receptor Affinity to Optimize Clinical Risk-Benefit When Targeting Alpha-Fetoprotein-Positive Liver CancerRoslin Y Docta, Tiago Ferronha, Joseph P Sanderson, et al.
Plos One|April 4, 2024
Selection, engineering, and in vivo testing of a human leukocyte antigen-independent T-cell receptor recognizing human mesothelinMartyn J Hiscox, Alexandra Wasmuth, Chris L Williams, et al.
Protein & Cell|January 8, 2011
High affinity soluble ILT2 receptor: a potent inhibitor of CD8(+) T cell activationRuth K Moysey, Yi Li, Samantha J Paston, et al.
Blood|June 18, 2013
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanomaGerald P Linette, Edward A Stadtmauer, Marcela V Maus, et al.
Science Translational Medicine|August 9, 2013
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cellsBrian J Cameron, Andrew B Gerry, Joseph Dukes, et al.
Nature Medicine|May 8, 2012
Monoclonal TCR-redirected tumor cell killingNathaniel Liddy, Giovanna Bossi, Katherine J Adams, et al.
Nature Medicine|July 21, 2015
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myelomaAaron P Rapoport, Edward A Stadtmauer, Gwendolyn K Binder-Scholl, et al.
Pageof 3